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Abstract
Background: Idiopathic macular holes are an important cause of blindness. They have an annual incidence of 8 per
100,000 individuals, and prevalence of 0.2 to 3.3 per 1000 individuals with visual impairment. The condition occurs
more frequently in adults aged 75 years or older. Macular holes can be repaired by surgery in which the causative
tractional forces in the eye are released and a temporary bubble of gas is injected. To promote successful hole
closure individuals may be advised to maintain a face-down position for up to 10 days following surgery. The aim
of this study is to determine whether advice to position face-down improves the surgical success rate of closure of
large (>400 μm) macular holes, and thereby reduces the need for further surgery.
Methods/Design: This will be a multicentre interventional, comparative randomised controlled clinical trial
comparing face-down positioning with face-forward positioning.
At the conclusion of standardised surgery across all sites, participants still eligible for inclusion will be allocated
randomly 1:1 to 1 of the 2 treatment arms stratified by site, using random permuted blocks of size 4 or 6 in equal
proportions. We will recruit 192 participants having surgery for large macular holes (>400 μm); 96 in each
of the 2 arms of the study. The primary objective is to determine the impact of face-down positioning on the
likelihood of closure of large (≥400 μm) full-thickness macular holes following surgery.
Discussion: This will be the first multicentre randomised control trial to investigate the value of face-down
positioning following macular hole standardised surgery.
Trial registration: UK CRN: 17966 (date of registration 26 November 2014).
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Introduction
Background
Idiopathic macular holes are an important cause of
blindness. They have an annual incidence of 8 per
100,000 individuals [1], and a prevalence of 0.2 [2] to 3.3
[3] per 1000 individuals with visual impairment. The
condition occurs more frequently in adults aged 75 years
or older [2]. Macular holes can have a devastating im-
pact on quality of life and independence but can be
repaired by surgery in which the causative tractional
forces in the eye are released and a temporary bubble of
gas is injected. To promote successful hole closure indi-
viduals may be advised to maintain a face-down position
for up to 10 days following surgery. However, face-down
positioning can be arduous [4] and associated with sig-
nificant adverse effects [5], and evidence of its value is
lacking. A recent Cochrane review [6] highlighted the
need for an appropriately designed, adequately powered
randomised controlled clinical trial to determine with
confidence its value. The review reported that estimated
effects were in favour of positioning but differences were
not statistically significant for smaller macular holes. It
concluded that face-down positioning may improve the
likelihood of successful surgery for large macular holes
(400 μm or greater in diameter) and highlighted the
need for an appropriately designed, adequately powered
randomised controlled clinical trial to determine with
confidence the value of advice to position face-down.
Rationale
The benefit of face-down positioning to the success of
surgery is unproven; evidence to guide individuals on its
impact is lacking and advice offered by clinicians varies
widely. The current lack of evidence with which to guide
patients has led to a lack of consensus among clinicians
and wide variation in clinical practice.
To address the limitations in the evidence we will per-
form a trial to determine whether advice to position
face-down, as opposed to face-forward, improves the
probability of macular hole closure at 3 months after
surgery, and so reduces the need for further surgery. We
will test whether advice to position face-down results in
a better outcome than an inactive face-forward position
following surgery for large macular holes (≥400 μm).
A previous pilot randomised controlled trial (RCT) [7]
has demonstrated the feasibility of this definitive RCT.
We have chosen to include only large macular holes
(≥400 μm) because the available evidence suggests that
face-down positioning is of more relevance to larger
holes than for smaller macular holes [7–9]. In addition,
the role of surgery in the management of smaller macu-
lar holes may be influenced in the future by the intro-
duction of enzymatic vitreolysis techniques; intra-ocular
injection of ocriplasmin can help induce closure in up to
40 % of smaller macular holes [10]. However, this ap-
proach is not designed for larger holes, the management
of which is likely to involve surgery for the foreseeable
future.
The proposed trial has been designed taking into ac-
count the views of individuals with macular holes and
clinicians. The pilot study suggested a benefit of posi-
tioning following surgery for large macular holes. Previ-
ous pilot study subjects were invited to form a Patient
Advisory Panel to advise on the design and methodology
of this new RCT. Both patients and clinicians indicated
that randomisation to either face-down positioning for
as long as 10 days, or conversely to no positioning at all,
would adversely affect recruitment to the trial because
these alternatives are typically considered too arduous or
would present too high a risk of non-closure, respect-
ively. Instead, we have reached a consensus, based on
the approach used by Guillaubey et al [8], on the alter-
natives of 5 days positioning either face-down or in an
inactive face-forward position.
For the primary outcome we have chosen successful
closure of the macular hole because, according to our
Patient Advisory Panel, this is directly relevant to pa-
tients; hole closure is essential for a favourable impact
on sight and determines whether further surgery is re-
quired. Although visual acuity is a relevant measure of
functional outcome, its validity is limited to some extent
in the short term by the confounding influence of sec-
ondary lens opacity and does not directly determine the
need for further surgery.
We have chosen not to attempt to measure objectively
the compliance of subjects with positioning. This is be-
cause self-reported compliance is of unknown reliability,
and objective monitoring risks influencing behaviour ar-
tificially and unpredictably. Instead, we have taken the
pragmatic approach to determine the value of the advice
to patients regarding position. However, following the
period of positioning we will ask subjects to say retro-
spectively how easy they found it to maintain their allo-
cated position (on a scale of 0 (very difficult) to 10 (very
easy). We will also assess their quality of life using the
National Eye Institute Visual Function Questionnaire
(VFQ-25).
The trial will benefit patients by providing reliable in-
formation on the value of positioning following surgery
for large macular holes, thereby enabling them to make
an appropriately informed choice about the management
of their condition.
The research will benefit the National Health Service
(NHS) because by determining the value of face-down
positioning we can expect to improve the likelihood of
prompt successful surgery and hence reduce the amount
of additional resource required for further clinical man-
agement and associated costs.
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Objectives
The aim is to determine whether advice to position face-
down improves the surgical success rate of closure of
large (≥400 μm) macular holes, and thereby reduces the
need for further surgery.
Primary objective
The primary objective is to determine the impact of
face-down positioning on the likelihood of closure of
large (≥400 μm) full-thickness macular holes following
surgery.
Secondary objective
The secondary objective is to determine the impact of face-
down positioning on sight, quality of life and wellbeing.
Methods/Design
This will be a multicentre interventional, comparative
randomised controlled clinical trial comparing face-down
positioning with face-forward positioning.
We will recruit 192 participants having surgery for
large macular holes (≥400 μm); 96 in each of the 2 arms
of the study.
Inclusion criteria
1. Presence of an idiopathic full-thickness macular
hole, greater than or equal to 400 μm in diameter as
measured by optical coherence tomography (OCT).
2. Patients electing to have surgery for a macular hole,
with or without simultaneous phacoemulsification
and intra-ocular lens implant.
3. Ability and willingness to position face-down or in
an inactive face-forward position.
Exclusion criteria
1. Age-related macular degeneration; glaucoma;
diabetic retinopathy; retinal degeneration;
amblyopia; previous vitrectomy surgery
(refractive error, lens opacity and previous use
of ocriplasmin are not exclusion criteria).
2. Traumatic macular hole.
3. History of visual loss suggesting macular hole
duration longer than 12 months.
4. Presence of a retinal tear identified during surgery
for which postoperative positioning is advised.
Informed consent
Eligible candidates will be approached at their baseline
visit by the clinical team, provided with information about
the trial and invited to participate. They will be given time
to consider their decision and the opportunity to ask
questions. Investigators will ensure that information about
equipoise is provided impartially so as to avoid potential
bias by influencing compliance with advice to position.
Should candidates elect to participate, informed consent
will be obtained (see Additional file 1) at the time of listing
for surgery. Candidates will understand that that although
consenting to participate in the trial, they will be formally
enrolled only if the inclusion and exclusion criteria are still
met following surgery.
We will not be recruiting/consenting subjects who we
feel lack capacity.
The surgery will involve vitrectomy (using instruments
of any gauge), internal limiting membrane (ILM) peeling
(with or without staining by a vital dye), fluid-air exchange
and injection of octafluoropropane (C3F8) 14 % gas. Vi-
trectomy may be combined with phacoemulsification and
intra-ocular lens implant.
Subjects will be randomised immediately following
surgery, unless exclusion criteria are met during surgery.
Intervention
The intervention is advice to adopt face-down position-
ing (see Additional file 2): subjects will be advised to
maintain a face-down position for a total of at least 8
consecutive or non- consecutive hours a day for 5 days
following surgery.
The comparator is advice to adopt face-forward posi-
tioning (see Additional file 3): subjects will be advised to
maintain a face-forward position, inactive, for at least 8
consecutive or non-consecutive hours a day for 5 days
following surgery.
Subjects in either group will be allowed a 15-minute
break (every hour) from their allocated position. In the
position-free-time we will advise subjects to avoid the
face-up position.
Face-down or face-forward positioning will be advised
during waking hours only, not during sleep. We will ad-
vise subjects to avoid the face-up position during sleep.
Investigators will explain positioning to candidates prior
to surgery, providing written instructions with diagrams.
Randomisation
Eligible candidates will be invited to participate and to
sign the consent form prior to surgery.
At the conclusion of standardised surgery across all
sites, participants still eligible for inclusion will be allo-
cated randomly 1:1 to one of the 2 treatment arms (refer
to the flow diagram in Additional file 4) stratified by site,
using random permuted blocks of size 4 or 6 in equal
proportions.
Randomisation will be performed using a secure be-
spoke online randomisation service implemented by the
PCTU (Pragmatic Clinical Trials Unit). Each site will be
provided with a unique log-in username and password
to access the service. Online randomisation will be
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available 24 hours a day, 7 days a week apart from short
periods of scheduled maintenance. Access to the service
will be restricted to staff as delegated by the Principal
Investigator (PI). They will input the participant ID and
details required for randomisation, and then will be
presented with immediate on-screen randomisation.
The randomisation system will have built-in checks to
check that (1) the participant ID is not a duplicate, and (2)
the date of birth is within the eligible age set in the
protocol.
Once the subject has been randomised, the enrolment
of this subject will be documented on the enrolment log.
An Email will be automatically generated to notify the
Chief Investigator’s (CIs) team and PCTU of all partici-
pants randomised to the trial.
Masking
Subjects and clinicians will be unmasked to treatment
allocation.
Investigators assessing the primary endpoint by grad-
ing of OCT scans will be masked to treatment allocation.
This will be achieved by electronic capture of OCT im-
ages which are presented anonymously to the grading
clinicians. Each clinician will be masked to their colleagues
grading. Postoperative hole closure will be determined ac-
cording to the presence (open) or absence (closed) of any
gap between the opposing edges of the hole. No measure-
ment is involved. In the event of disagreement between
clinicians, the opinion of a third clinician (also masked)
will be sought.
Follow-up
Subjects will attend for follow-up assessment as part of
the trial at 3 months following surgery. Their surgical
teams will manage their routine postoperative clinical
care in the meantime.
The primary outcome, macular hole closure, will be
determined by masked assessment of OCT scans acquired
at 3 months.
Unit of analysis
All ocular assessments relate to the study eye. In the
event that a subject is having surgery for bilateral macu-
lar holes (which are not operated on simultaneously),
the first eye to be operated on during the trial will be the
study eye.
Data collection
Table 1 shows the schedule of assessments.
Pre-operative data collection:
 Demographic data (age, sex, ethnicity)
 Laterality
 Duration of symptoms
 Best-corrected visual acuity (BCVA) measured using
Snellen charts at a standard distance of 6 metres
 OCT with recording of minimal hole diameter
(see Additional file 5)
Outcome measures
Primary outcome
The primary outcome will be anatomical closure of the
macular hole, determined at 3 months after surgery by
masked assessment of OCT scans.
Secondary outcomes
 Further surgery for macular hole, performed or
planned
 BCVA using standard Snellen chart at 6 metres
 Patient-reported experience of positioning at
3 months
 Patient-reported health and quality of life as assessed
at baseline and at 3 months using the National Eye
Institute Visual Function Questionnaire (VFQ-25)
End of study definition
The end of the study will be at the final assessment of
the final subject.
Table 1 Schedule of assessments
Assessment Preoperative Surgery 3 months
postoperative
Age x
Sex x
Ethnicity x
Laterality x
Duration of symptoms x
BCVA x x
Lens status: phakic/
pseudophakic
x x
Informed consent x
Surgery x
Randomisation x
Macular hole diameter on OCT x
Macular hole status (closed;
open flat; open elevated)
x
QoL VFQ-25 questionnaire x x
Subject-reported experience
of positioning
x
If primary repair of macular
hole failed, was second
operation performed/planned
x
BCVA best-corrected visual acuity, OCT optical coherence tomography, QoL
quality of life, VFQ-25 Visual Functional Questionnaire
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Statistical considerations
Sample size and power calculation
Clinical consensus is that face-down positioning would be
recommended if there were a difference of 15 % in success
rates. This is the smallest clinically relevant treatment
difference that we wish to detect. Previous studies [8] indi-
cate that successful closure of large macular holes without
advice to position face-down is 80 %. A study with 86
patients per group has 85 % power to detect a difference
between 80 % in the face-forward positioning arm and
95 % in the face-down positioning arm. With a 10 % loss to
follow-up, we are aiming to recruit 96 patients in each arm.
Analysis
Baseline characteristics will be tabulated in the two
treatment arms.
Proportions of macular hole closures at 3 months will be
compared between treatment arms using logistic regres-
sion adjusting for age and sex, with site as a random effect.
Visual acuity at 3 months will be compared using lin-
ear regression adjusting for age, sex, and baseline visual
acuity, with site as a random effect. We will also adjust
for surgery type in the logistic regression analysis. Ques-
tionnaire scores assessed at 3 months will be compared
using linear regression adjusting for age and sex, with
site as a random effect.
The numbers of participants who decline to partici-
pate, fail screening, or withdraw or are lost to follow-up
will be recorded in a Consolidated Standards of Report-
ing Trials (CONSORT) flow-chart.
The analyses will be on an intention-to-treat basis, and
every effort will be made to collect complete data. If any
outcome data are missing we will analyse available sub-
jects only (this is unbiased under a missing-at-random
assumption where missingness depends only on variables
adjusted for in the analysis), but we will also perform
secondary analyses investigating the missing-at-random
assumption and involving further baseline covariates if
necessary.
OCT scans will be anonymised and sent to two inde-
pendent retinal surgeons who will grade the macular
hole as closed; open and flat (without a cuff of subretinal
fluid), or open and elevated (with a cuff of subretinal
fluid). The readers will be masked to the identity and
treatment allocation of the subject. In the event of any
disparity in grading, a third independent retinal surgeon,
also masked to identity and treatment allocation, will
arbitrate.
A formal statistical analysis plan will be signed off by
the Trial Steering Committee prior to analysis.
Safety considerations
Random allocation to the alternatives of face-down and
face-forward positioning presents a possible safety issue
because of the uncertainly over which is more effective,
and the known adverse effects of prolonged face-down
positioning. We have addressed these risks by advising a
minimum of inactive face-forward positioning for all
subjects, and only an 8-hour total minimum period of
face-down positioning.
Data handling and record keeping
 Confidentiality
Information related to participants should be kept
confidential and managed in accordance with the
Data Protection Act, NHS Caldecott Principles, The
Research Governance Framework for Health and
Social Care, and the conditions of Research Ethics
Committee (REC) approval.
 Record retention and archiving
All study documents are to be retained for a period
of 5 years following conclusion of the study.
Following the submission of the end of study report
the sponsor will arrange for archiving of the Trial
Master File in accordance with the sponsor’s
process. The sponsor will also notify the local PIs
that the Investigator Site Files (ISFs) may be
archived. The ISFs will be retained and archived at
site in accordance with the Trusts’ procedures.
Following the end of the retention period the
sponsor will notify the PIs in writing that the
required retention period has completed and that
documents can be destroyed. A copy of the
instruction to the Trust Archivist to destroy the ISF
will be requested.
Products, devices, techniques and tools
Devices
Spectral domain ocular coherence tomography (SD-OCT)
will be used at the various sites to determine the preope-
rative size of the macular hole, and whether surgery has
been successful in terms of hole closure at 3 months.
The size of the macular hole is defined as its minimum
horizontal diameter. This is its linear width measured
using the OCT caliper function along a line that bisects
the hole in the horizontal meridian and is parallel to the
retinal pigment epithelium (see Additional file 5).
Tools
The VFQ-25 is a reliable and valid 25-item version of the
51-item National Eye Institute Visual Function Question-
naire (NEI-VFQ).
Safety reporting
Adverse event (AE)
Safety reporting will adhere to the sponsor’s standard
operating procedures. If the AE is not defined as serious,
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it will be recorded in the study file and the parti-
cipant will be followed-up by the research team. The
AE will be documented in the participants’ medical
notes.
Serious adverse event (SAE)
A SAE is defined as an untoward occurrence that:
(a)Results in death;
(b)Is life-threatening;
(c)Requires hospitalisation or prolongation of existing
hospitalisation;
(d)Results in persistent or significant disability or
incapacity;
(e)Consists of a congenital anomaly or birth defect; or
(f ) Is otherwise considered medically significant by the
investigator.
An SAE occurring to a research participant will be re-
ported to the main REC where in the opinion of the CI
the event was:
 Related – that is, it resulted from administration of
any of the research procedures, and
 Unexpected – that is, the type of event is not listed
in the protocol as an expected occurrence.
Expected AEs include the following:
Ocular discomfort; epiphora; periocular swelling;
diplopia; ptosis
Subconjunctival or intra-ocular hemorrhage
Corneal abrasion
Retinal or choroidal tear or detachment
Wound leak
Ocular hypotony or raised intra-ocular pressure/
glaucoma
Overfill or underfill of intra-ocular gas tamponade
Intra-ocular or extra-ocular inflammation or infection
Intra-ocular neovascularisation
Lens opacity, subluxation or dislocation of lens or lens
implant
Persistent or recurrent macular hole
Visual field defect or other disturbance of sight
Discomfort of joints, neck, back or limbs
SAEs that are considered to be ‘related’ and ‘un-
expected’ are to be reported to the sponsor within
24 hours of learning of the event using the following
Email address: pharmacovigilance@moorfields.nhs.uk
and to the main REC within 15 days, in line with the
required timeframe. SAEs will be documented in the
participants’ medical notes and the Case Report Form
(CRF).
Urgent safety measures
The CI may take urgent safety measures to ensure the
safety and protection of the clinical trial subjects from
any immediate hazard to their health and safety. The
measures should be taken immediately. In this instance,
the approval of the REC prior to implementing these
safety measures is not required. However, it is the re-
sponsibility of the CI to inform the sponsor and main
REC (via telephone) of this event immediately.
The CI has an obligation to inform both the main
REC in writing within 3 days, in the form of a substan-
tial amendment. The sponsor must be sent a copy of the
correspondence with regards to this matter.
Annual safety reporting
The CI will send the Annual Progress Report to the
main REC using the National Research Ethics Service
(NRES) template (the anniversary date is the date on the
‘favourable opinion’ letter from the REC) and to the
sponsor.
Overview of the safety reporting responsibilities
The CI has the overall safety oversight responsibility and
will ensure that safety monitoring and reporting is con-
ducted in accordance with the sponsor’s requirements.
Monitoring and auditing
The study will be monitored in line with the study moni-
toring plan, written by the PCTU quality assurance
(QA) manager and agreed by the study sponsor. The
PCTU has provisionally identified this study as being
medium risk.
Trial organisation
Trial management committee
James Bainbridge: Chief Investigator, Moorfields Eye
Hospital, London, UK
Saruban Pasu: Co-investigator, NIHR Biomedical Re-
search Centre (BRC) at Moorfields Eye Hospital NHS
Foundation Trust and UCL Institute of Ophthalmology,
London, UK
Catey Bunce: Co-investigator and statistician, Moorfields
Eye Hospital, London, UK
Ann Thomson: Senior Trial Manager, Pragmatic Clinical
Trials Unit, London, UK
Irene Simmonds: Trial Co-ordinator, Pragmatic Clinical
Trials Unit, London, UK
Richard Hooper: Statistician, Pragmatic Clinical Trials
Unit, London, UK
Mike Waring: Data Manager, Pragmatic Clinical Trials
Unit, London, UK
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Trial steering committee
Noemi Lois: Consultant Ophthalmic Surgeon, Belfast
Health and Social Care Trust, Belfast, Northern Ireland,
UK.
Simon Skene: Senior Statistician, University College
London, London, UK.
Roy Smith: Lay Person, UK.
This team will also perform the duties of a data man-
agement committee.
Finance and funding
The trial is funded by the National Institute for Health
Research Health Technology Assessment (NIHR HTA)
Research for Patient Benefit scheme.
Indemnity
The sponsor is Moorfields Eye Hospital (MEH) NHS
Foundation Trust, which participates in the Clinical
Negligence Scheme for Trusts (CNST), run by the
NHS Litigation Authority, which pools the risk of
clinical negligence claims. NHS indemnity (for negli-
gent harm) will cover MEH employees, both substan-
tive and honorary, who are working in the course of
their NHS employment and in respect of conducting
research projects, which must have received NHS
Permission. MEH will not accept liability for any ac-
tivity that has not been properly registered and Trust
approved.
Ethics
Random allocation to the alternatives of face-down or
face-forward positioning presents a possible ethical issue
because of the uncertainty over which is safer and more
effective. In particular, there is some concern that indi-
viduals with large holes randomised to non-positioning
may be less likely to benefit from hole-closure. We have
addressed this concern by ensuring that subjects not al-
located to face-down positioning are advised to maintain
an inactive face-forward position, which has been an ac-
ceptable standard for previous trials. If the results dem-
onstrate that positioning face-down is more effective
than positioning inactively face-forward we can conclude
that it is also likely to be more effective than not posi-
tioning at all.
Applications to the UK’s main REC (NRES Committee
London – Westminster) and the local Moorfields Re-
search Management Committee have received favourable
opinion (REC reference 14/LO/2061).
We will perform the study in accordance with the eth-
ical principles in the Research Governance Framework
for Health and Social Care, Second Edition, 2005 and its
subsequent amendments.
Dissemination of research findings
The results will be disseminated at clinical meetings,
and by publication in a peer-reviewed journal.
Discussion
The research team combines the strengths of experi-
enced eye specialists with the expertise of the PCTU,
and the active involvement of patients to ensure that the
trial addresses their needs. The trial will benefit patients
by providing reliable information on the value of postur-
ing following surgery for large macular holes, thereby
enabling them to make an appropriately informed choice
about the management of their condition.
Trial status
The authors confirm that the trial will start recruiting
from May 2015 onwards.
Additional files
Additional file 1: Consent form. (DOCX 38 kb)
Additional file 2: Examples of face-down seated and face-down
lying. (DOCX 446 kb)
Additional file 3: Examples of face-forward reading and face-forward
watching TV. (DOCX 414 kb)
Additional file 4: Flow diagram of PIMS trial. (DOCX 39 kb)
Additional file 5: OCT image of macular hole. (DOCX 627 kb)
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